Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Rituximab 55Cyclophosphamide 41Lenalidomide 25Vincristine 23Doxorubicin 22Prednisone 21Etoposide 16ibrutinib 12Gemcitabine 12fludarabine phosphate 10fludarabine 10Peripheral Blood Stem Cell Transplantation 10Carboplatin 10Bendamustine Hydrochloride 10Ifosfamide 9Filgrastim 8polatuzumab vedotin 7obinutuzumab 7Oxaliplatin 7Mycophenolic Acid 7Methotrexate 6Cyclosporine 6venetoclax 5tafasitamab 5Vorinostat 5Radiotherapy 5R-CHOP protocol 5Prednisolone 5Melphalan 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × Homoharringtonine × Clear all
NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Affiliated Hospital of Zhejiang University

Phase 1/2 Not yet recruiting
62 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡